Investigational product demonstrated superior hemodialysis vascular access outcomes compared with autologous arteriovenous ...

This work demonstrates the great potential of LEO for developing high-quality bioengineered tissues for various research and clinical applications, such as disease modeling and therapeutic ...

The proposed offering of the common stock and warrants described above is being offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-267225) filed with the ...

Humacyte ( (HUMA) ) has provided an announcement. Humacyte, Inc. has announced a $15 million registered direct offering, selling common stock ...

Johns Hopkins Medicine scientists who arranged for 48 human bioengineered heart tissue samples to spend 30 days at the ...

This research could lead to advancements in bioengineered tissues for various applications, including disease modeling, drug testing, and therapeutic implantation. Dr. Chang is a board-certified ...

Humacyte’s Q3earnings callrepresents a pivotal moment as the company navigates regulatory challenges while striving to advance its bioengineered tissue programs. The FDA's recent findings ...

BLA for the Treatment of Vascular Trauma is ongoing - - Results from the V007 Phase 3 clinical trial of the ATEV in arteriovenous (AV) access for hemodialysis patients presented at American Society of ...

The Kobe University bioengineer Hasunuma Tomohisa says, "To obtain a high-yield and low-cost supply, it is desirable to produce it in bioengineered microorganisms which can be grown in fermenters." ...